Edward J Stepanski
Overview
Explore the profile of Edward J Stepanski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
1662
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Graetz I, Anderson J, McKillop C, Stepanski E, Paladino A, Tillmanns T
Gynecol Oncol
. 2018 Jun;
150(2):311-317.
PMID: 29903391
Objective: Nearly 1 in 5 patients hospitalized for ovarian cancer surgery are readmitted for complications that may have been prevented with monitoring. We conducted a randomized controlled feasibility trial to...
2.
Samuels B, Chawla S, Somaiah N, Staddon A, Skubitz K, Milhem M, et al.
Cancer
. 2017 Aug;
123(23):4640-4647.
PMID: 28832986
Background: This phase 2, single-arm, multicenter study was designed to determine the treatment activity and safety of single-agent pazopanib in patients with unresectable or metastatic liposarcoma. Methods: Eligible patients had...
3.
Pennell N, Dicker A, Tran C, Jim H, Schwartz D, Stepanski E
Am Soc Clin Oncol Educ Book
. 2017 Jun;
37:144-154.
PMID: 28561720
Accompanied by the change in the traditional medical landscape, advances in wireless technology have led to the development of telehealth or mobile health (mHealth), which offers an unparalleled opportunity for...
4.
Walker M, Pohl G, Houts A, Peltz G, Miller P, Schwartzberg L, et al.
Psychooncology
. 2016 Jan;
26(6):755-762.
PMID: 26790987
Background: Patients with non-small cell lung cancer (NSCLC) experience adverse physical symptoms because of cancer, cancer treatment, and comorbidities. The relations among Cancer-Related Symptoms, Functional Impairment, and Psychological Symptoms in...
5.
Walker M, Reyes C, Kerr J, Satram-Hoang S, Stepanski E
Int J Dermatol
. 2014 Mar;
53(11):e499-506.
PMID: 24602078
Background: The primary systemic treatments for advanced melanoma have been chemotherapy and immunotherapy. New agents are currently in development. Objectives: This study aimed to characterize treatment patterns and outcomes across...
6.
Schwartzberg L, Wang G, Somer B, Blakely L, Wheeler B, Walker M, et al.
Clin Breast Cancer
. 2013 Nov;
14(1):13-9.
PMID: 24268206
Background: In this phase II study, we explored efficacy and toxicity of combined endocrine and low-dose metronomic chemotherapy therapy consisting of fulvestrant and capecitabine in estrogen and/or progesterone receptor-positive, HER2-negative...
7.
Miller P, Balu S, Buchner D, Walker M, Stepanski E, Schwartzberg L
J Med Econ
. 2013 Aug;
16(10):1179-89.
PMID: 23919632
Objective: Understanding the value patients place on avoiding various aspects of chemotherapy induced nausea and vomiting (CINV) can help medical professionals assess whether current and emerging treatments are acceptable based...
8.
Harrison M, George D, Walker M, Chen C, Korytowsky B, Kirkendall D, et al.
Clin Genitourin Cancer
. 2013 Jul;
11(4):441-50.
PMID: 23856102
Background: New targeted therapeutics approved for metastatic renal cell carcinoma (mRCC) offer multiple options in each line of therapy; however, there are few prospective data beyond the first-line settings, and...
9.
Walker M, Stepanski E, Reyes C, Satram-Hoang S, Houts A, Schwartzberg L
Ther Adv Hematol
. 2013 Apr;
2(3):129-39.
PMID: 23556084
Background: The impact on health related quality of life (HRQoL) of rituximab maintenance (R-M) versus observation (OBS) after induction for treatment of follicular lymphoma (FL) is unclear. Methods: We reviewed...
10.
Schwartzberg L, Tauer K, Hermann R, Makari-Judson G, Isaacs C, Beck J, et al.
Clin Cancer Res
. 2013 Feb;
19(10):2745-54.
PMID: 23444220
Purpose: We assessed adding the multikinase inhibitor sorafenib to gemcitabine or capecitabine in patients with advanced breast cancer whose disease progressed during/after bevacizumab. Experimental Design: This double-blind, randomized, placebo-controlled phase...